Drug Information Association Logo
Corporate Tagline

CardioVascular Safety – What are the Key Issues Regarding Blood Pressure Assessment During Clinical Development

| Online

« Back to Listing

Overview 

Continuing Education credit or Certificate Program units are not available for Archived Webinars

This archived webinar will be available for purchase through October 31, 2014. Broadcast time is 1 hour 28 minutes.


This webinar focuses on recent safety considerations regarding blood pressure increases during drug development, how blood pressure should ideally be assessed during development, regulatory considerations, technical aspects, and case examples. 





 This webinar was developed in collaboration with the Cardiac Safety Research Consortium (CSRC)

Who Should Attend 

Physicians, pharmacists, nurses, regulatory experts and others involved in:

  • Development of pharmaceutical products
  • Safety/Pharmacovigilance
  • Drug Development
  • Risk Management

Learning Objectives 

At the conclusion of this webinar, participants should be able to:

  • Explain the current safety issues surrounding drug-induced BP elevations
  • Discuss how BP is best assessed during clinical development
  • Describe the ideal technical approaches to assessing BP changes during development

Contact Information 

Printable Registration Form

Registration Questions
Toll Free 1.888.257.6457
Phone +1.215.442.6100
Fax +1.215.442.6199
Monday-Friday 8:30AM-8:00PM ET
CustomerService@diahome.org

For information on this archived webinar
DIA North America
Carolyn Callahan
Phone +1.215.442.6194
Carolyn.Callahan@diahome.org

Technical Requirements 

Click here for minimum system requirements.

Presenter(s) 

Previous Next

Agenda  

Day 1 Thursday, Nov 07, 2013

  • 11:00AM - 11:59PM

    CardioVascular Safety – What are the Key Issues Regarding Blood Pressure Assessment During Clinical Development

    Speaker(s):

    • Philip T. Sager, MD, FACC
      President; CVI Consulting Professor, Stanford University School of Medicine
      Sager Consulting Experts , United States
    • William B White, MD, FACC
      Professor of Medicine and Division Chief, Hypertension and Clinical Pharmacology
      University of Connecticut School of Medicine, United States
    • Illustrative Case Studies: Establishing Systematic Methods for Defining Adverse Blood Pressure Effects of Drugs
      Michael A. Weber, MD, FACC
      Professor of Medicine
      State University of New York, United States

Registration Fees 

Other Fees

Government (Full Time) Individual
$125.00
Charitable Nonprofit/Academia Individual
$175.00
Group Site
$799.00
Group Plus
$995.00

Member

Member Industry Individual
$250.00

Non-Member

NonMember Industry Individual
$295.00
Group Discounts

  • Group site registration is a license for ONE internet login allowing multiple viewers from one location.
  • Group Plus is a license for up to FIVE internet logins allowing one or more viewers at each login location.


CANCELLATIONS
No refunds will be provided in the event of a participant’s cancellation since all costs for this webinar have been prepaid by DIA. DIA reserves the right to modify or cancel programs and/or substitute presenters or panelists. DIA is not responsible for failure to deliver programs due to circumstances beyond its control.

Participants with Disabilities: Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.

Register Online

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top